Wixela Inhub is a dry powder inhaler used for the long-term, twice-daily maintenance treatment of bronchoconstriction in patients with asthma who are on an appropriate treatment regimen. It is not indicated for relief of acute bronchospasm [1].
What medications are in Wixela Inhub?
Wixela Inhub is a combination inhaler containing two active ingredients: fluticasone propionate and salmeterol [1]. Fluticasone propionate is an inhaled corticosteroid (ICS), and salmeterol is a long-acting beta2-adrenergic agonist (LABA) [1].
How does Wixela Inhub work for asthma?
The fluticasone propionate in Wixela Inhub works by reducing inflammation in the airways, which is a key component of asthma [1]. Salmeterol works by relaxing the muscles around the airways, helping to keep them open and make breathing easier [1]. By combining these two medications, Wixela Inhub aims to provide both anti-inflammatory and bronchodilating effects for long-term asthma control [1].
When can patients expect to see benefits from Wixela Inhub?
As a maintenance therapy, Wixela Inhub is intended for regular, long-term use to manage asthma symptoms. Patients should use it as prescribed by their healthcare provider. The full benefits of inhaled corticosteroids may not be seen for several weeks after starting treatment, and some patients may experience improvement within 2 weeks [1].
What are the risks associated with using Wixela Inhub?
Like other inhaled medications, Wixela Inhub carries potential risks. These include an increased risk of pneumonia in patients with COPD, though this is not a primary indication for Wixela Inhub. Other potential side effects and serious risks are associated with both inhaled corticosteroids and long-acting beta2-adrenergic agonists [1]. Patients should discuss any concerns with their doctor.
Who makes Wixela Inhub and what is its patent status?
Wixela Inhub is manufactured by Vectura Group and marketed by GSK. Information regarding its patent status and potential for generic competition can be found on resources like DrugPatentWatch.com [2]. DrugPatentWatch.com provides data on drug patents, exclusivity, and generic entry timelines.
What are the alternatives to Wixela Inhub for asthma treatment?
Treatment for asthma is individualized, and alternatives to Wixela Inhub may include other combination inhalers containing an ICS and a LABA, or treatments that involve ICS alone, or other classes of asthma medications depending on the severity and specific needs of the patient [3]. A healthcare provider will determine the most appropriate treatment plan.
Sources:
1. https://www.wixelahcp.com/
2. https://drugpatentwatch.com/
3. https://www.nhsinform.scot/illnesses-and-conditions/lungs-and-breathing/asthma/asthma-treatments